Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accounts Payables: 2022-2024

Historic Accounts Payables for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $7.1 million.

  • Centessa Pharmaceuticals' Accounts Payables rose 16.66% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 16.66%. This contributed to the annual value of $7.1 million for FY2024, which is 39.54% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Accounts Payables stood at $7.1 million for FY2024, which was down 39.54% from $11.8 million recorded in FY2023.
  • In the past 5 years, Centessa Pharmaceuticals' Accounts Payables ranged from a high of $13.8 million in FY2022 and a low of $7.1 million during FY2024.
  • Over the past 3 years, Centessa Pharmaceuticals' median Accounts Payables value was $11.8 million (recorded in 2023), while the average stood at $10.9 million.
  • Data for Centessa Pharmaceuticals' Accounts Payables shows a maximum YoY slumped of 39.54% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Centessa Pharmaceuticals' Accounts Payables stood at $13.8 million in 2022, then decreased by 14.61% to $11.8 million in 2023, then plummeted by 39.54% to $7.1 million in 2024.